Armata Pharmaceuticals, INC. (ARMP) — SEC Filings

Q: What are the key financial highlights for Armata Pharmaceuticals, INC.?

Key financial highlights for Armata Pharmaceuticals, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Armata Pharmaceuticals, INC.?

Key executives at Armata Pharmaceuticals, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Armata Pharmaceuticals, INC. stock?

Risk factors for Armata Pharmaceuticals, INC. (ARMP) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Armata Pharmaceuticals, INC.?

Forward-looking statements and predictions from Armata Pharmaceuticals, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Armata Pharmaceuticals, INC.. Recent 10-K filing on Mar 25, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Armata Pharmaceuticals, INC. on SEC EDGAR

Overview

Armata Pharmaceuticals, INC. (ARMP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: Armata Pharmaceuticals, Inc. (ARMP) is a late clinical-stage biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections. The company has completed three Phase 2 clinical trials for its lead candidates, AP-PA02 and AP-SA02. For AP-PA02, target

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Armata Pharmaceuticals, INC. is neutral.

Filing Type Overview

Armata Pharmaceuticals, INC. (ARMP) has filed 3 10-K, 20 8-K, 6 10-Q, 2 DEF 14A, 2 SC 13D/A with the SEC between Mar 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

Armata's Phage Therapy Shows Promise in Lung Infections — 10-K · Mar 25, 2026 Risk: high
Armata Pharmaceuticals, Inc. (ARMP) is a late clinical-stage biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant bac
8-K Filing — 8-K · Dec 1, 2025
Armata's Net Loss Doubles to $49.5M, Raising Going Concern Doubts — 10-Q · Nov 12, 2025 Risk: high
Armata Pharmaceuticals, Inc. (ARMP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $49.5 million, compared t
Armata Pharmaceuticals Files 8-K — 8-K · Oct 22, 2025 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as A
Armata Pharmaceuticals Files 8-K — 8-K · Sep 11, 2025 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on September 10, 2025, to report under Regulation FD. The filing indicates the company's common stock trades under the
Armata's Q2 Loss Widens Amidst R&D Spend, Secures New Loan — 10-Q · Aug 12, 2025 Risk: high
Armata Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as it remains a clini
Armata Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2025 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details
Armata Pharmaceuticals Files 8-K — 8-K · May 19, 2025 Risk: medium
Armata Pharmaceuticals, Inc. filed an 8-K on May 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
Armata Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
Armata Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first
Armata Pharmaceuticals Files 8-K — 8-K · May 1, 2025 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on May 1, 2025, reporting other events and financial statements. The company, formerly known as AmpliPhi Biosciences C
Armata Pharmaceuticals Files Proxy Statement for June 12 Meeting — DEF 14A · Apr 28, 2025 Risk: low
Armata Pharmaceuticals, Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting of stockholders scheduled for June 12, 2025. The fil
Merck to Acquire Armata Pharmaceuticals for $1.7B — 8-K · Apr 2, 2025 Risk: medium
Armata Pharmaceuticals, Inc. announced on April 2, 2025, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for approximately $
Armata Pharmaceuticals Files 2024 10-K — 10-K · Mar 21, 2025 Risk: medium
Armata Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly AmpliPhi Biosciences Corp, is based in Los Angel
Armata Pharmaceuticals Files 8-K: Material Agreement & Financial Obligation — 8-K · Mar 12, 2025 Risk: medium
On March 12, 2025, Armata Pharmaceuticals, Inc. entered into a material definitive agreement and incurred a direct financial obligation. The filing indicates a
Armata Pharmaceuticals Files 8-K — 8-K · Dec 19, 2024 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on December 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does n
Armata Pharma Appoints New CMO, Elects Director — 8-K · Dec 4, 2024 Risk: medium
Armata Pharmaceuticals, Inc. announced on December 2, 2024, the appointment of Dr. Paul L. Bolte as Chief Medical Officer and the election of Dr. David J. Ebers
Armata Pharmaceuticals Announces Material Agreement and Officer Changes — 8-K · Nov 15, 2024 Risk: medium
Armata Pharmaceuticals, Inc. announced on November 12, 2024, the entry into a material definitive agreement and changes in its board of directors and officer ap
Innoviva Amends Stake in Armata Pharmaceuticals — SC 13D/A · Nov 14, 2024 Risk: medium
Innoviva, Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of Armata Pharmaceuticals, Inc. as of November 14, 20
Armata Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
Armata Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly AmpliPhi Biosciences Corp, is involved in biological
Armata Pharmaceuticals Files 8-K — 8-K · Nov 12, 2024 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does n
Armata Pharmaceuticals Files 8-K on Officer/Director Changes — 8-K · Oct 3, 2024 Risk: medium
Armata Pharmaceuticals, Inc. filed an 8-K on October 3, 2024, reporting events as of September 30, 2024. The filing indicates changes related to the departure o
Armata Pharmaceuticals Announces CMO Departure, Appoints Interim — 8-K · Sep 26, 2024 Risk: medium
Armata Pharmaceuticals, Inc. announced on September 22, 2024, the departure of its Chief Medical Officer, Dr. Jonathan R. Peterson. Concurrently, the company ap
Armata Pharmaceuticals Files 8-K — 8-K · Aug 26, 2024 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on August 26, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
Armata Pharma Reports Officer/Director Changes & Compensation — 8-K · Aug 15, 2024 Risk: medium
Armata Pharmaceuticals, Inc. filed an 8-K on August 15, 2024, reporting events as of July 31, 2024. The filing primarily concerns the departure of directors or
Armata Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
Armata Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
Armata Pharmaceuticals Appoints New CMO, Adds Directors — 8-K · Jul 25, 2024 Risk: medium
Armata Pharmaceuticals, Inc. announced on July 22, 2024, the appointment of Dr. Paul L. Bolte as Chief Medical Officer and the election of Dr. Bolte and Ms. Jen
Armata Pharmaceuticals Reports Shareholder Vote — 8-K · Jun 14, 2024 Risk: medium
Armata Pharmaceuticals, Inc. filed an 8-K on June 14, 2024, reporting on a matter submitted to a vote of its security holders on June 12, 2024. The filing does
Armata Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
Armata Pharmaceuticals, Inc. (ARMP) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Armata Pharmaceuticals, Inc. filed a 10-Q report for the period
Armata Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Shareholders — DEF 14A · Apr 29, 2024 Risk: low
Armata Pharmaceuticals, Inc. (ARMP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Annual Meeting scheduled for June 12, 2024, at 8:30 a.m. P
Armata Pharmaceuticals Files 8-K — 8-K · Mar 22, 2024 Risk: low
Armata Pharmaceuticals, Inc. filed an 8-K on March 22, 2024, reporting on shareholder nominations and financial statements. The company, formerly AmpliPhi Biosc
Armata Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk: low
Armata Pharmaceuticals, Inc. (ARMP) filed a Annual Report (10-K) with the SEC on March 21, 2024. Armata Pharmaceuticals, Inc. filed its annual report on Form 10
Armata Pharmaceuticals Enters Material Agreement, Creates Financial Obligation — 8-K · Mar 4, 2024 Risk: medium
Armata Pharmaceuticals, Inc. entered into a material definitive agreement on March 4, 2024, which also created a direct financial obligation for the company. Th
Innoviva Files 13D/A for Armata Pharmaceuticals — SC 13D/A · Mar 4, 2024 Risk: medium
Innoviva, Inc. has amended its Schedule 13D filing regarding Armata Pharmaceuticals, Inc. on March 4, 2024. The filing indicates a change in the beneficial owne

Risk Profile

Risk Assessment: Of ARMP's 32 recent filings, 3 were flagged as high-risk, 18 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

Dr. Paul L. Bolte
Dr. David J. Ebersole
Dr. Steven A. Deitcher
Dr. Jonathan R. Peterson
Dr. David J. E. Davies
Ms. Jennifer L. D. Allison
Dr. Steven L. St. Clair

Industry Context

Armata Pharmaceuticals operates in the highly competitive biotechnology sector, specifically focusing on the emerging field of bacteriophage therapeutics. This niche is gaining traction due to the escalating global crisis of antibiotic resistance, a problem that traditional antibiotics are increasingly failing to address. The industry is characterized by significant R&D investment, long development timelines, and stringent regulatory hurdles. Companies in this space are vying to establish the efficacy and safety of novel treatment modalities.

Top Tags

financials (8) · 8-K (5) · corporate-governance (5) · pharmaceuticals (5) · disclosure (4) · 10-Q (4) · Biotechnology (3) · sec-filing (3) · biotech (3) · Antibiotic Resistance (2)

Key Numbers

Market Value of Non-Affiliate Voting Stock: $21.1M — As of June 30, 2025, indicating a smaller market capitalization.
Shares Outstanding: 36,632,775 — As of March 18, 2026, providing current share count.
Cystic Fibrosis Foundation Award: $5.0M — Received in 2024, supporting AP-PA02 development.
Statistical Significance for P. aeruginosa Reduction: P=0.05 — In AP-PA02 Phase 2 Tail wind study at day 17 (post-hoc analysis).
Net Loss: $49.5M — for the nine months ended September 30, 2025, significantly increased from $21.5M in 2024
Cash and Cash Equivalents: $14.8M — as of September 30, 2025, insufficient to fund operations for 12 months
Accumulated Deficit: $377.2M — as of September 30, 2025, indicating significant historical losses
Change in fair value of Convertible Loan: $15.2M — negative impact for the nine months ended September 30, 2025, compared to a $17.3M gain in 2024
Interest Expense: $11.8M — for the nine months ended September 30, 2025, up from $7.5M in 2024
August 2025 Loan: $15.0M — new loan from Innoviva Strategic Opportunities LLC
March 2025 Loan: $10.0M — new loan from Innoviva Strategic Opportunities LLC
Annual Interest Rate: 14.0% — on both the August 2025 and March 2025 loans
Research and Development Expenses: $17.6M — for the nine months ended September 30, 2025, decreased from $26.0M in 2024
Grant and Award Revenue: $3.8M — for the nine months ended September 30, 2025, slightly down from $3.9M in 2024
Revenue: $0 — No revenue for Q2 2025 and YTD 2025, consistent with prior periods.

Related Companies

INVA · MRK

Frequently Asked Questions

What are the latest SEC filings for Armata Pharmaceuticals, INC. (ARMP)?

Armata Pharmaceuticals, INC. has 33 recent SEC filings from Mar 2024 to Mar 2026, including 20 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ARMP filings?

Across 33 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Armata Pharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Armata Pharmaceuticals, INC. (ARMP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Armata Pharmaceuticals, INC.?

Key financial highlights from Armata Pharmaceuticals, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for ARMP?

The investment thesis for ARMP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Armata Pharmaceuticals, INC.?

Key executives identified across Armata Pharmaceuticals, INC.'s filings include Dr. Paul L. Bolte, Dr. David J. Ebersole, Dr. Steven A. Deitcher, Dr. Jonathan R. Peterson, Dr. David J. E. Davies and 2 others.

What are the main risk factors for Armata Pharmaceuticals, INC. stock?

Of ARMP's 32 assessed filings, 3 were flagged high-risk, 18 medium-risk, and 11 low-risk.

What are recent predictions and forward guidance from Armata Pharmaceuticals, INC.?

Forward guidance and predictions for Armata Pharmaceuticals, INC. are extracted from SEC filings as they are enriched.